UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psor

Arthritis care & research (2010), 2011-11, Vol.63 (S11), p.S64-S85

Mease, Philip J.

2011

Volltextzugriff (PDF)

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

Current opinion in rheumatology, 2015-03, Vol.27 (2), p.127-133

Mease, Philip J

2015

Volltextzugriff (PDF)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1112-1124

2019

Volltextzugriff (PDF)

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria

Seminars in arthritis and rheumatism, 2016-12, Vol.46 (3), p.319-329

2016

Volltextzugriff (PDF)

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2015-09, Vol.386 (9999), p.1137-1146

2015

Volltextzugriff (PDF)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Arthritis research & therapy, 2018-03, Vol.20 (1), p.47-11, Article 47

2018

Volltextzugriff (PDF)

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

The New England journal of medicine, 2014-06, Vol.370 (24), p.2295-2306

2014

Volltextzugriff (PDF)

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Journal of rheumatology, 2018-10, Vol.45 (10), p.1389-1396

2018

Volltextzugriff (PDF)

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture

American journal of human genetics, 2015-12, Vol.97 (6), p.816-836

2015

Volltextzugriff (PDF)

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Journal of the American Academy of Dermatology, 2013-11, Vol.69 (5), p.729-735

2013

Volltextzugriff (PDF)

Biologic Therapy for Psoriatic Arthritis

Rheumatic diseases clinics of North America, 2015-11, Vol.41 (4), p.723-738

Mease, Philip J., MD

2015

Volltextzugriff (PDF)

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis

Arthritis research & therapy, 2019-05, Vol.21 (1), p.118-118, Article 118

2019

Volltextzugriff (PDF)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research

Arthritis research & therapy, 2020-02, Vol.22 (1), p.18-18, Article 18

2020

Volltextzugriff (PDF)

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Annals of the rheumatic diseases, 2020-01, Vol.79 (1), p.88-93

2020

Volltextzugriff (PDF)

Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment

Current opinion in rheumatology, 2017-07, Vol.29 (4), p.304-310

Mease, Philip J

2017

Volltextzugriff (PDF)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Rheumatic & musculoskeletal diseases open, 2023-02, Vol.9 (1), p.e002735

2023

Volltextzugriff (PDF)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Acta dermato-venereologica, 2022-04, Vol.102, p.adv00698-adv00698

2022

Volltextzugriff (PDF)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies

Arthritis research & therapy, 2023-08, Vol.25 (1), p.153-13, Article 153

2023

Volltextzugriff (PDF)

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry

Arthritis research & therapy, 2021-09, Vol.23 (1), p.1-236, Article 236

2021

Volltextzugriff (PDF)

B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application

Journal of rheumatology, 2008-07, Vol.35 (7), p.1245

Mease, Philip J

2008

Volltextzugriff (PDF)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

Arthritis research & therapy, 2021-07, Vol.23 (1), p.190-190, Article 190

2021

Volltextzugriff (PDF)

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial

Journal of rheumatology, 2009-02, Vol.36 (2), p.398-409

2009

Volltextzugriff (PDF)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Trials, 2022-09, Vol.23 (1), p.743-14, Article 743

2022

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia

Journal of rheumatology, 2008-03, Vol.35 (3), p.502

2008

Volltextzugriff (PDF)

1 – 25 von 658

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(587)
Mit Volltextzugriff
(404)

Publikationsform

Artikel
(613)
Buchkapitel
(40)
Bücher
(5)

Sprache

Englisch
(658)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(461)
Science & Technology
(461)
Rheumatology
(420)
Humans
(367)
Psoriatic Arthritis
(327)
Psoriasis
(207)
Female
(163)
Male
(156)
Treatment Outcome
(150)
Arthritis, Psoriatic - Drug Therapy
(142)
Middle Aged
(141)
Adult
(135)
Biological And Medical Sciences
(115)
Medical Sciences
(115)
Patients
(114)
Severity Of Illness Index
(106)
Antirheumatic Agents - Therapeutic Use
(101)
Arthritis
(101)
Diseases Of The Osteoarticular System
(101)
Dermatology
(94)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Biologic Therapy for Psoriatic Arthritis

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry

B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia

Suchergebnisse filtern